• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173379 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
& n% n- A, a0 j* Y! e# N* Y
% I$ @8 _" J7 U9 ]/ H7 J* U' s1 O" A! `) l/ G
Sub-category:! h! |9 Y5 A9 u
Molecular Targets
: Y% p( c7 b: ^' h5 t- S
4 `) D& W- e- F7 s3 t" \" c4 Z  ^7 T! ~0 M  m+ M. d* P
Category:+ E  M5 @/ _/ C5 H0 x
Tumor Biology * C5 [  C% f- i7 Q

0 r: X5 R  j3 u3 U# m# ^. g9 G7 b: S# |" `4 ^* H: V4 Y% e
Meeting:3 `$ r) {* X. R6 o; O8 r3 G/ j
2011 ASCO Annual Meeting
9 b3 d. Q+ p8 L. T3 {( f
! g4 c/ K! j5 Q. u( Y1 A1 l; L/ n. P3 Y
Session Type and Session Title:1 i$ M8 H% e  [" F5 t2 H. L) x
Poster Discussion Session, Tumor Biology
: e- r: X: Y0 c0 }7 y3 Q
1 f& K6 n! I) N
- j/ n& Y5 M  z+ g9 k. u% X% `Abstract No:3 o- i6 r1 U  {. a0 F
10517
9 X; w5 u, q- ?8 A7 }* ?6 {# G  z1 R6 @2 k; K

4 j1 q: f0 z$ ^Citation:
7 u3 n7 y8 ~+ t# K% q: qJ Clin Oncol 29: 2011 (suppl; abstr 10517)
8 K7 f" t+ P- T/ C; b" b9 B3 S1 J# m3 o, r+ g( i

4 ]0 y5 B' [" q! t' hAuthor(s):
% `0 q8 @# k, |% A' sJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 3 v2 U) _7 d, b9 ]

9 q0 `. ]1 Z; `" `3 P: m4 v# F* y0 f" [: X2 n1 A; f, a* W9 ]

# w+ b( O. ^, z5 [Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.8 ^! _7 K. M/ `

) r: j. j7 `4 D* ^) |Abstract Disclosures
0 F7 H; L5 i/ r- x2 Z
4 l6 ]5 x, O( W1 {+ B, pAbstract:
: ]$ w; C: t3 l
5 n* c) ?5 `  l/ d4 q- w( B, H/ B
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
' ]/ g5 B2 T# l! S
  t$ r; {6 F2 g: a9 c, m; E 3 L- j& W9 Y' a4 C- F
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
- C8 W. W7 e; o) q8 Y+ x8 `3 Q没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
& Q3 ~) @3 K' {  \) z' p9 _2 |3 [% [' s
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
9 C# c% k- J  U3 w7 h) J易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
5 a3 ?5 S" B! x9 A1 J. ~& jALK一个指标医院要900多 ...
( f# M/ O/ C; X# A: q! J
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
7 @8 ~1 w2 O3 O9 R! i
/ c4 m# u6 j% U- [现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表